Early Treatment With Glatiramer Acetate Improved Outcomes in CIS (Clinically Isolated Syndrome)

October 25, 2010
By: SHARON WORCESTER, Internal Medicine News Digital Network

Patients with clinically isolated syndrome who receive early treatment with glatiramer acetate have more than a 40% reduction in the risk of developing multiple sclerosis, compared with those whose treatment is delayed, according to findings from a prospectively planned 5-year follow-up of patient in the phase III PreCISe study.

After a 2-year extension phase of the 3-year double-blind, placebo-controlled study, 33% of 80 patients who had received early treatment with glatiramer acetate (GA) developed clinically definite multiple sclerosis (CDMS), compared with 50% of 118 patients who began treatment at the end of the initial 3-year double-blind phase. Each patient received 20 mg of GA daily by subcutaneous injection.

Read More

***********************************************************

"Providing You with 'MS Views and News', is what we do"

Keep Informed and up-to-date with information concerning

 Multiple Sclerosis when registered at

the MS Views and News  website.

****************************************************************

Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

. ****************************************************************